Day 3 Program

Rapid Fire 7

Day 3: December 11, 2025

1:00 PM–2:00 PM CST

Stars at Night 1-2

Session Details

Oral presentations of high impact clinical trials and translation science.
The text of the abstracts will be posted on Monday, November 24.

Moderator

Aleix Prat, Hospital Clinic Barcelona, Barcelona, Spain

RF7-01

Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study

Hope Rugo, City of Hope Duarte Cancer Center, Duarte, CA

RF7-02

Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor (EPIK-B5): Phase III, randomized, double-blind, placebo-controlled, multicenter study

Michelino De Laurentiis, Department of Breast and Thoracic Oncology, National Cancer Institute “Fondazione Pascale”, Naples, Italy

RF7-03

Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

François-Clément Bidard, Institut Curie, Paris, France

RF7-04

Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial

Barbara Pistilli, Gustave Roussy, Villejuif, France

RF7-05

Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial

Nicholas C Turner, Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom

RF7-06

Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burden

Véronique Dieras, Centre Eugène Marquis, Rennes, France

RF7-07

Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival

Angela DeMichele, University of Pennsylvania, Philadelphia, PA